このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Nuvalent マネジメント

マネジメント基準チェック /34

Nuvalent'sの CEO はJim Porterで、 Feb2020年に任命され、の在任期間は 4.33年です。の年間総報酬は$ 9.38Mで、 6.4%給与と93.6%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.12%を直接所有しており、その価値は$ 5.81M 。経営陣と取締役会の平均在任期間はそれぞれ3年と3.4年です。

主要情報

Jim Porter

最高経営責任者

US$9.4m

報酬総額

CEO給与比率	6.4%
CEO在任期間	4.3yrs
CEOの所有権	0.1%
経営陣の平均在職期間	3yrs
取締役会の平均在任期間	3.4yrs

経営陣の近況

Recent updates

Nuvalent: Making Precise Progress In Its Oncology Pipeline

Jun 24

Nuvalent: NVL-655 Could Bring Blockbuster Potential

Jun 14

Here's Why We're Not Too Worried About Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

Apr 22

Here's Why We're Not At All Concerned With Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

Jun 10

We're Interested To See How Nuvalent (NASDAQ:NUVL) Uses Its Cash Hoard To Grow

Feb 24

Here's Why We're Not Too Worried About Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

Sep 13

Nuvalent GAAP EPS of -$0.38 beats by $0.03

Aug 10

Here's Why We're Not At All Concerned With Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

May 28

We're Hopeful That Nuvalent (NASDAQ:NUVL) Will Use Its Cash Wisely

Oct 29

CEO報酬分析

Nuvalent の収益と比較して、Jim Porter の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	-US$146m
Dec 31 2023	US$9m	US$603k	-US$126m
Sep 30 2023	n/a	n/a	-US$114m
Jun 30 2023	n/a	n/a	-US$100m
Mar 31 2023	n/a	n/a	-US$89m
Dec 31 2022	US$5m	US$580k	-US$82m
Sep 30 2022	n/a	n/a	-US$73m
Jun 30 2022	n/a	n/a	-US$66m
Mar 31 2022	n/a	n/a	-US$57m
Dec 31 2021	US$5m	US$424k	-US$46m
Sep 30 2021	n/a	n/a	-US$36m
Jun 30 2021	n/a	n/a	-US$28m
Mar 31 2021	n/a	n/a	-US$27m
Dec 31 2020	US$759k	US$335k	-US$15m

報酬と市場: Jimの総報酬 ($USD 9.38M ) は、 US市場 ($USD 8.45M ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Jimの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Jim Porter (48 yo)

4.3yrs

在職期間

US$9,376,872

報酬

Dr. James R. Porter, also known as Jim, Ph.D. has been Chief Executive Officer and President of Nuvalent, Inc. since February 1, 2020 and has been Director since February 2020. He joined Nuvalent during co...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
James Porter	CEO, President & Director	4.3yrs	US$9.38m	0.12% $ 6.1m
Matthew Shair	Founder	7.3yrs	US$688.18k	2.57% $ 133.4m
Alexandra Balcom	CFO & Treasurer	3.4yrs	US$3.54m	0% $ 0
Christopher Turner	Chief Medical Officer	3.3yrs	US$3.60m	0.022% $ 1.2m
Benjamin Lane	Senior Vice President of Technical Operations	1.9yrs	データなし	データなし
Deborah Miller	Chief Legal Officer & Secretary	3yrs	US$1.69m	0.052% $ 2.7m
Matthew Metivier	Senior Vice President of Human Resources	2.3yrs	データなし	データなし
Darlene Noci	Chief Development Officer	3.4yrs	データなし	0.052% $ 2.7m
Henry Pelish	Senior Vice President of Drug Discovery	1.3yrs	データなし	データなし
John Soglia	Senior Vice President of Translational Development	1.3yrs	データなし	データなし
Perrin Wilson	Senior Vice President of Business Development & Strategy	less than a year	データなし	データなし

3.0yrs

平均在職期間

48yo

平均年齢

経験豊富な経営陣: NUVLの経営陣は経験豊富であると考えられます ( 3年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
James Porter	CEO, President & Director	4.3yrs	US$9.38m	0.12% $ 6.1m
Matthew Shair	Founder	7.3yrs	US$688.18k	2.57% $ 133.4m
Sapna Srivastava	Independent Non-Executive Director	2.9yrs	US$503.18k	0% $ 0
Anna Protopapas	Independent Chairman	2.3yrs	US$523.18k	0% $ 0
Pasi Antero Janne	Member of Scientific Advisory Board	no data	データなし	データなし
D. Gilliland	Independent Non-Executive Director	3.4yrs	US$495.68k	0% $ 0
Michael Meyers	Member of Scientific Advisory Board & Independent Director	1.7yrs	US$494.36k	0% $ 0
Cameron Wheeler	Independent Non-Executive Director	7.3yrs	US$499.45k	データなし
Joseph Pearlberg	Independent Non-Executive Director	3.4yrs	US$494.00k	データなし
Emily Conley	Independent Director	2.3yrs	US$495.90k	0.000010% $ 518.8
D. Camidge	Member of Scientific Advisory Board	no data	データなし	データなし
Aaron Hata	Member of Scientific Advisory Board	no data	データなし	データなし

3.4yrs

平均在職期間

55yo

平均年齢

経験豊富なボード: NUVLの取締役会は経験豊富であると考えられます ( 3.4年の平均在任期間)。

Nuvalent マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Independent Director notifies of intention to sell stock

Chief Legal Officer & Secretary exercised options and sold US$528k worth of stock

Nuvalent, Inc., Annual General Meeting, Jun 12, 2024

Independent Director notifies of intention to sell stock

Chief Development Officer notifies of intention to sell stock

Founder notifies of intention to sell stock

Recent updates

Nuvalent: Making Precise Progress In Its Oncology Pipeline

Independent Director notifies of intention to sell stock

Nuvalent: NVL-655 Could Bring Blockbuster Potential

Chief Legal Officer & Secretary exercised options and sold US$528k worth of stock

Nuvalent, Inc. Receives U.S. FDA Breakthrough Therapy Designation for NVL-655

Nuvalent, Inc., Annual General Meeting, Jun 12, 2024

Here's Why We're Not Too Worried About Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

Price target increased by 10% to US$102

Independent Director notifies of intention to sell stock

Price target increased by 8.6% to US$92.13

Nuvalent: Pivotal NSCLC Programs Progressing With Additional Data In 2024

Price target increased by 7.4% to US$84.83

Nuvalent, Inc. Initiates the Phase 2 Portion of Alkove-1 Clinical Trial for Patients with Alk-Positive Nsclc and Other Solid Tumors

Is Nuvalent, Inc. (NASDAQ:NUVL) Trading At A 36% Discount?

Chief Development Officer notifies of intention to sell stock

Founder notifies of intention to sell stock

Chief Development Officer notifies of intention to sell stock

New minor risk - Share price stability

Price target increased by 11% to US$59.14

Companies Like Nuvalent (NASDAQ:NUVL) Can Afford To Invest In Growth

Nuvalent to Present Preliminary Data from ALKOVE-1 Phase 1/2 Clinical Trial of NVL-655 at 35th AACR-NCI-EORTC Symposium

Nuvalent Initiates the Phase 2 Portion of ARROS-1 Clinical Trial for Patients with Ros1-Positive NSCLC and Other Solid Tumors

New major risk - Revenue and earnings growth

Price target increased by 8.7% to US$50.83

Chief Legal Officer & Secretary notifies of intention to sell stock

Price target increased by 8.7% to US$50.80

Chief Legal Officer & Secretary notifies of intention to sell stock

Chief Development Officer notifies of intention to sell stock

Here's Why We're Not At All Concerned With Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

Chief Development Officer exercised options and sold US$125k worth of stock

Price target increased by 10% to US$46.75

Chief Development Officer exercised options and sold US$113k worth of stock

Chief Development Officer exercised options and sold US$77k worth of stock

Chief Development Officer exercised options and sold US$86k worth of stock

We're Interested To See How Nuvalent (NASDAQ:NUVL) Uses Its Cash Hoard To Grow

Chief Legal Officer & Secretary notifies of intention to sell stock

Chief Development Officer exercised options and sold US$85k worth of stock

Chief Legal Officer & Secretary exercised options and sold US$51k worth of stock

Chief Development Officer exercised options and sold US$121k worth of stock

Nuvalent Inc. Announces Publication in Cancer Discovery Detailing Design and Characterization of ROS1-selective inhibitor NVL-520

Chief Development Officer exercised options and sold US$130k worth of stock

Price target increased to US$43.67

High number of new directors

Chief Legal Officer & Secretary exercised options and sold US$287k worth of stock

Nuvalent, Inc. Reports Preliminary Phase 1 Clinical Data from ARROS-1 Trial that Support Best-In-Class Potential of NVL-520 for Patients withROS1-Positive NSCLC

Chief Development Officer exercised options and sold US$85k worth of stock

Nuvalent, Inc. Currently Enrolling Patients in the Phase 1 Portion of Its Arros-1 Study, A Phase 1/2 Clinical Trial

Chief Development Officer exercised options and sold US$72k worth of stock

Here's Why We're Not Too Worried About Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

Nuvalent, Inc. Present Preliminary Phase 1 Data from ARROS-1 Clinical Trial of NVL-520 at 34th EORTC-NCI-AACR Symposium and Announces Pipeline Updates

Nuvalent GAAP EPS of -$0.38 beats by $0.03

Nuvalent, Inc. Presents New Preclinical Data Supporting Potential Best-In-Class Profile for ALK-Selective Inhibitor NV-655 At IASLC 2022 World Conference on Lung Cancer Annual Meeting

Nuvalent, Inc. Announces Leadership Promotions

Insider exercised options and sold US$278k worth of stock

Nuvalent, Inc.(NasdaqGS:NUVL) dropped from Russell 2000 Growth Index

Nuvalent, Inc. Announces Clinical Progress on Parallel Lead Programs NVL-520 and NVL-655 for NSCLC and Solid Tumor Cancers

Here's Why We're Not At All Concerned With Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

Now 21% undervalued after recent price drop

Chief Medical Officer exercised options to buy US$117k worth of stock.

Now 25% undervalued after recent price drop

Nuvalent, Inc., Annual General Meeting, Jun 16, 2022

High number of new directors

High number of new directors

Nuvalent, Inc. Appoints Anna Protopapas as Chair of Board of Directors

Nuvalent to Present New Preclinical Data on ROS1-Selective Inhibitor NVL-520 and ALK-Selective Inhibitor NVL-655 at AACR Annual Meeting 2022

Insider exercised options and sold US$68k worth of stock

Nuvalent Appoints Emily Drabant Conley to Board of Directors

Nuvalent, Inc Announces First Patient Dosed in ARROS-1 Phase 1/2 Clinical Trial of NVL-520, its Novel ROS1-selective Inhibitor

We're Hopeful That Nuvalent (NASDAQ:NUVL) Will Use Its Cash Wisely

マネジメント基準チェック /34